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Objectives: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate com-
prised of the microtubule inhibitory cytotoxic agent DM1 and trastuzumab which, in 
addition to its antitumor properties, targets T-DM1 to HER2–overexpressing cells. The 
overall safety profile of T-DM1 was investigated in the phase III EMILIA trial (com-
paring T-DM1 [n= 496] to capecitabine plus lapatinib [CAP+LAP, n= 495]) in patients 
with HER2-positive locally advanced or metastatic breast cancer (MBC) previously 
treated with trastuzumab and a taxane, and the phase II TDM4450g trial (comparing 
T-DM1 [n= 67] to trastuzumab plus docetaxel [TRAZ+DOCE, n= 70]) in patients with 
previously untreated MBC. Both trials demonstrated clinically meaningful differ-
ences between T-DM1 and its comparators. The objectives were to estimate and 
compare the Canadian costs of managing the treatment-related adverse events 
(AEs) of T-DM1 as reported in the two trials, from the perspective of Canadian 
public payers. MethOds: An Excel based spreadsheet model was utilized for the 
analysis. Costing information was obtained from the literature, clinical experts, and 
Canadian standard costing sources. Costs were reported as 2012 CAD. The AEs that 
were considered were all treatment-related grade ≥ 3 AEs as well as grade 2 AEs that 
occurred in ≥ 5% of patients in both arms of either study. Results: The manage-
ment of treatment-related AEs as reported in the EMILIA trial resulted in higher per 
patient costs ranging from $3,060 - $10,499 for CAP+LAP versus $1,376 - $2,463 for 
T-DM1, yielding savings of $1,684-$8,036. In the TDM4450g trial, the management 
of treatment-related AEs resulted in higher per patient costs ranging from $5,124 
- $27,617 for TRAZ+DOCE versus $798 - $2,215 for T-DM1, yielding savings of $4,326-
$25,402. cOnclusiOns: This analysis demonstrated that utilizing T-DM1 for the 
management of HER2-positive metastatic breast cancer results in significant cost 
savings of related AEs management due to the improved safety profile compared 
to CAP+LAP and TRAZ+DOCE.
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Objectives: Stereotactic radiation therapy is an innovative technique with high 
therapeutic potential due to excellent local control and increased survival rate. A 
cost analysis investigating stereotactic radiation therapy modalities either with lin-
ear accelerator (Cone Beam Computed Tomography (CBCT), Exac-trac) or Cyberknife 
was conducted. MethOds: The cost-analysis was performed prospectively based 
on a multicenter study. Patients included were treated for lung carcinoma (T1-T2, N0, 
M0). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Only direct costs were taken into account. Productivity 
losses of personnel involved in the process, costs of administrative personnel, costs 
of logistics and general management were not taken into account. Time horizon 
included radiation therapy (preparation for radiation therapy and the fraction itself). 
All costs were given in 2011 euros. Uncertainty was captured by one-way and proba-
bilistic sensitivity analyses using a non-parametric bootstrap method. Results: 
113 patients were enrolled in 11 French centers from April 2009 to December 2011. 
98 economic questionnaires were exploitable. The costs of preparation for stereo-
tactic radiation therapy were 430€ (SD: 101€ ) with Cyberknife and 433€ (SD: 199€ ) 
with linear accelerator. When required, costs of implementation of fiducial markers 
with one/two days of inpatient care were 1,619€ . The costs of stereotactic radia-
tion therapy (all fractions included) were 1,811€ (SD: 760€ ) with Cyberknife and 
817€ (SD:403€ ) with linear accelerator. Costs per fraction were 550€ (SD: 224€ ) with 
Cyberknife and 201€ (SD: 97€ ) with linear accelerator. Depreciation periods of the 
accelerator played a major role in costs. cOnclusiOns: This is to our knowledge 
the first study highlighting costs incurred by different stereotactic radiation therapy 
modalities in lung cancers. Cost-effectiveness studies have to be conducted in order 
to shed further light on which modality to focus on.
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Objectives: Everolimus plus exemestane (EVE+EXE) recently received approval for 
the treatment of patients with HR+/HER2- advanced breast cancer that recurs or 
progresses during/after non-steroidal aromatase inhibitors. This study was designed 
to evaluate the expected costs of managing adverse events during EVE+EXE therapy 
and single-agent chemotherapy in the western European region. MethOds: An 
economic model was developed to estimate per-patient cost of managing adverse 
events for patients receiving EVE+EXE or chemotherapies. Adverse event rates for 
EVE+EXE were collected from the phase III BOLERO-2 trial. Adverse event rates for 
capecitabine, docetaxel, and doxorubicin chemotherapies were collected from 
published clinical trial data. Grade 3/4 adverse events with at least 2% prevalence 
during any of these treatments were included in the study. The adverse event rate 
direct cell death compared with rituximab (Rtx) and is pending regulatory approval 
(in combination with chlorambucil (Clb)) for the treatment of patients with pre-
viously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has 
shown > 85% reduction in the risk of progression, relapse or death in comparison 
to treatment with Clb alone (HR 0.14), a broadly accepted treatment option for many 
patients with co-existing medical conditions. In a majority of markets the health 
economic consequences will be assessed in terms of affordability. MethOds: A 
health economic model was developed analyzing the cost impact of obinutuzumab 
on further lines of treatment due to the number of reduced refractory patients com-
pared to Clb and Rtx. Market share information for obinutuzumab, ofatumumab, 
Rtx, Clb and Bendamustine and the different relevant combinations were entered 
for Germany and Canada (Ontario province only). Results: Based on a 39% reduc-
tion in numbers of refractory patients treated with obinutuzumab+Clb compared 
to Rtx+Clb cost savings per year per patient (PYPP) for further line treatments in 
Canada (Ontario) range between Ca$950 and Ca$3,091, which leads to maximum 
cost savings for the whole eligible population (401 patients) up to $Ca1,239,491. 
In Germany the cost savings range PYPP between € 2,556 and € 8,318, which leads 
to maximum cost savings for the whole eligible population (1,302 patients) up to 
€ 10,830,036. The big difference in the cost savings PYPP between the two coun-
tries is mainly due to the different market share assumptions for ofatumumab. 
Key cost drivers were treatment duration and price/cost of further line treatments. 
Scenario analyses on cost, efficacy and market share data confirmed these find-
ings. cOnclusiOns: Obinutuzumab+Clb shows significant patient-relevant clini-
cal benefits and potential cost savings in further line treatments in patients with 
previously untreated CLL.
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Objectives: To assess the cost-effectiveness of the new transdermal therapeutic sys-
tem (TTS) of fentanyl and subcutaneous injections (SIs) of morphine hydrochloride in 
the treatment of chronic pain and predict potential budget impact of the implementa-
tion of fentanyl TTS in routine clinical practice. MethOds: The pharmacoeconomic 
model was developed based on the results of Russian observational study, included 
45 patients with terminal cancer: 25 patients received fentanyl TTS and 20 – SIs of 
morphine. At the first stage, the cost-effectiveness ratios (CERs) of therapies during 
the first month was measured as total costs of medicines and expenses for ambulance 
services for acute pain relief per one patient without side-effects. At the second stage, 
the CERs of therapies during subsequent three months was measured as costs of 
medicines per one unit of pain intensity (PI) reduction (visual pain scale). Results: 
During the first month of therapy the frequency of ambulance use was significantly 
lower in patients received fentanyl TTS (0.32 vs 1.05 per one patient per week in the 
morphine group), this was reflected in lower total costs (12 611, 42 RUB and 23,037.54 
RUB per one patient, respectively). Patients in the fentanyl TTS group were less likely 
to have side effects. The estimated CERs for fentanyl TTS and SIs of morphine were 
13,001.46 RUB and 27,756.07 RUB per one patient without vomiting and 23,354.47 
RUB and 82,276.93 RUB per one patient without constipation, respectively. Long-term 
treatment with fentanyl TTS was resulted in decreased PI as compared to SIs of mor-
phine. The three-month CERs were 4,897.05 RUB and 7,869.30 RUB per one unit of PI 
reduction, respectively. cOnclusiOns: The present study has demonstrated that 
administration of new transdermal therapeutic system of fentanyl has the better 
cost-effectiveness profile in the treatment of Russian cancer patients.
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Objectives: Chemotherapy-induced neutropenia (CIN), a commonly-occurring 
adverse event in cancer patients undergoing chemotherapy, and particularly febrile 
neutropenia (FN), have potentially life-threatening and costly consequences. The 
standard of care for patients at risk of FN comprises prophylactic administra-
tion of recombinant granulocyte colony-stimulating factor (G-CSF) with pegfil-
grastim, a long-acting formulation of G-CSF, and the most widely used in Europe. 
Lipegfilgrastim is a novel, pegylated and glycosylated long-acting G-CSF designed 
for use in the same patient population as pegfilgrastim. We developed a model to 
estimate the economic impact over five years of managing G-CSF-eligible chem-
otherapy patients at risk of FN with lipegfilgrastim rather than pegfilgrastim in 
Scotland. MethOds: The eligible patient population was estimated based on cancer 
incidence in Scotland and current uptake of G-CSF by patients initiating chemo-
therapy to prevent neutropenia. Drug, monitoring and event costs were taken from 
the British National Formulary, Unit Costs of Health and Social Care and Scottish 
National Tariff. As lipegfilgrastim was shown to be non-inferior to pegfilgrastim (in 
a phase III study in breast cancer patients), the efficacy and safety of pegfilgrastim 
and lipegfilgrastim were assumed to be identical. Non-statistically significant trends 
towards fewer neutropenic events and dose modifications with lipegfilgrastim were 
explored in scenario analyses. Results: The model estimated that 315 patients 
currently receive pegfilgrastim annually. A progressive increase in lipegfilgrastim 
uptake was associated with cost savings ranging from £2,814 in year 1 to £16,883 in 
year 5, totalling £61,904 over five years. Savings were attributable to the low drug 
acquisition cost of lipegfilgrastim. Using event rates from the pivotal phase III breast 
cancer study, scenario analyses suggested that using lipegfilgrastim instead of peg-
filgrastim generated savings of £145,312, avoided 81 neutropenic events (including 
11 occurrences of FN) and 50 dose modifications, and caused 34 additional treat-
ment-emergent adverse events. cOnclusiOns: Lipegfilgrastim was cost-saving 
compared with pegfilgrastim.
A402  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
index date for the comparator group was randomly chosen to reduce selection bias. 
A 1-year continuous health plan enrollment was required before and after the index 
date for both groups. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator groups using 1:1 propensity 
score matching (PSM). Results: Eligible patients (N= 384,596) were identified for 
the prostate cancer and comparison cohorts and after applying PSM, a total of 
112,693 patients were matched from each group and the baseline characteristics 
were well-balanced. Patients diagnosed with prostate cancer were more likely to be 
hospitalized (75.41% vs. 2.46%, p< 0.01), and report more emergency room (9.30% vs. 
5.45%, p< 0.01), outpatient (99.77% vs. 61.15%, p< 0.01) and pharmacy visits (85.65% 
vs. 63.77%, p< 0.01). Patients diagnosed with prostate cancer also incurred higher 
costs for inpatient ($2,216 vs. $695, p< 0.01), emergency room ($92 vs. $51, p< 0.01), 
outpatient ($3,364 vs. $1,462, p< 0.01), pharmacy ($582 vs. $413, p< 0.01) and total 
costs (6,162 vs. $2,571, p< 0.01) compared to the comparator group. cOnclusiOns: 
Patients diagnosed with prostate cancer were associated with a higher burden of 
illness compared to their matched controls during a period of 12 months.
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Objectives: Everolimus and axitinib are approved to treat patients with metastatic 
renal cell carcinoma (mRCC) following failure on various first-line therapies. This 
analysis assessed the cost of care with everolimus versus axitinib for second-line 
mRCC patients from a Canadian payer perspective. MethOds: Costs considered 
in this analysis included those related to drug acquisition and adverse events (AEs). 
Drug acquisition costs were based on the Ontario wholesaler price. Adverse event 
costs were based on the Ontario Case Costing Initiative and literature. Drug costs, 
adjusted for dose intensity, and AE costs, based on daily incidence rates, accrued 
for the duration of treatment in each arm; the sums of these costs were compared 
across treatments. The mean dose intensities, treatment durations and rates of 
AEs in the treatment arms were the calculated from trial data. Scenario analyses 
are presented to estimate the range of costs within the treatment arms. Costs are 
presented in 2011 Canadian dollars. Results: In the base case analysis, the total 
cost of treatment with everolimus was estimated to be $24,931 while the total cost 
of treatment with axitinib was $39,010. The primary driver of the cost discrepancy 
was axitinib’s high dose intensity, resulting in high drug acquisition costs. Despite 
analysis limitations, the trend of the results remained consistent across scenario 
analyses. When treatment duration was estimated from median progression-free 
survival estimates in each study’s post-sunitinib populations, the total cost of treat-
ment with everolimus was $8,339 less than with axitinib. Sensitivity analyses that 
assumed equivalent treatment durations between each arm also demonstrated 
lower overall treatment costs for everolimus patients. cOnclusiOns: The analysis 
demonstrates that everolimus provides a less costly treatment option than axitinib 
for patients requiring second-line therapy. Significant uncertainty remains regard-
ing axitinib’s treatment duration and dosing, which could result in higher costs to 
the health care system compared to everolimus.
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Objectives: Ipilumumab is a clinically proven treatment option for pre-treated 
metastatic melanoma (MM). Ipilumumab has clearly demonstrated survival ben-
efit, that is prolonged in a proportion of the responding patients. Karweit J and 
colleagues (2012) demonstrated that mean overall survival (OS) can be particularly 
useful for agents with a right-skewed survival curve where a subset of patients 
respond to treatment with long term survival. The research has demonstrated that 
several agents, including ipilimumab for MM, bevacizumab for non-small cell lung 
cancer, sorafenib for hepatocellular carcinoma, lenalidomide for multiple mye-
loma and trastuzumab for metastatic breast cancer (among others) have shown 
greater mean OS improvement than median OS improvement, reflecting the long 
term survival benefit for some patients. In this analysis we select oncologic agents 
that have demonstrated mean OS benefit in the above mentioned study and have 
received license in Mexico. We compare the relative economic value delivered by 
each asset, which broadly represent the therapeutic oncologic class. MethOds: 
The economic value of the analogues is estimated for the Mexican private per-
spective in terms of cost per month of mean OS versus comparators. The analy-
sis relies on the cost to treat to mean progression by the months of mean OS 
improvement. Results: Cost per month of OS for ipilimumab ($15,993 USD) when 
compared to bevacizumab, sorafenib, trastuzumab, sunitinib, lenalidomide and 
vemurafenib is below the average relative cost of the assets (range from $35,871 
to $9,845 USD). cOnclusiOns: This study demonstrates that ipilimumab is a 
competitive asset in terms of value for money. The analysis allows to evaluate 
within a clear and robust analytical framework, the reimbursement decisions 
across the oncologic therapeutic class in Mexico.
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Objectives: To measure the costs of two pilot interventions within the National 
Institutes of Health-funded Centers for Population Health and Health Disparities 
(CPHHD) designed to improve health outcomes in medically underserved commu-
estimates do not count multiple episodes of the same event. Costs of managing 
each adverse event were obtained from the literature and averaged across west-
ern European countries (UK, Germany, France, Italy, Belgium, Spain, Sweden, and 
Switzerland), where available. The costs were inflated to 2012 Euros (€ ). Results: 
Expected per-patient costs of managing adverse events within the first year of treat-
ment among patients with advanced breast cancer receiving EVE+EXE were € 730. 
Among patients receiving capecitabine, docetaxel, or doxorubicin as single-agent 
chemotherapy, expected per-patient costs were € 1721, € 2390, and € 1230, respectively. 
The most costly adverse event for patients treated with EVE+EXE was anemia (€ 152 
per patient). The most costly adverse event for patients treated with capecitabine, 
docetaxel, or doxorubicin was lymphocytopenia (€ 861 per patient), neutropenia 
(€ 821 per patient), and leukopenia (€ 382 per patient), respectively. cOnclusiOns: 
Expected costs of managing adverse events in patients with HR+/HER2- advanced 
breast cancer receiving EVE+EXE are about one-half to one-third of the costs for 
those receiving chemotherapies. This economic consideration can have important 
implications for health care spending in the advanced breast cancer setting.
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Objectives: To estimate the economic impact of managing chemotherapy patients 
at risk of neutropenia and eligible to receive Granulocyte-Colony Stimulating Factor 
(G-CSF) with lipegfilgatrim (LONQUEX, a new long-acting G-CSF) rather than peg-
filgastrim in Spain. MethOds: Both the BIA and CMA were conducted from the 
Spanish-payer’s perspective: they included direct drug cost, administration, neutro-
penic events and adverse event costs, but did not consider indirect costs. The drug 
acquisition cost of lipegfilgatrim used in the model was based on the anticipated 
price of lipegfilgatrim at the time of launch in Spain. All costs were expressed in 
EUROS-2013. A range of sensitivity, scenario and threshold analyses were performed. 
An additional analysis was performed within the BIA to explore the trend towards 
fewer dose modifications in the lipegfilgatrim arm of the XM22-03 trial. Results: 
The CMA shows that treating a patient with lipegfilgatrim instead of pegfilgrastim 
resulted in a cost saving of 650,06€ . At the population level, the BIA predicts that 
cost savings could range from 113.166€ in year 1 to 678.995€ in year 5, totaling to 
2.489.648€ over five years. Furthermore, the BIA shows a potential to avoid 50 dose 
modifications with the use of lipegfilgatrim instead of pegfilgrastim. The model is 
most sensitive to the cost of pegfilgrastim and lipegfilgatrim, but results are robust, 
with the model estimating cost savings over a wide range of inputs. When the trend 
towards decreased NE and increased AE with lipegfilgatrim vs pegfilgrastim reported 
in the XM22-03 trial is explored, cost savings was about 30% compared to the default 
scenario, reaching 3.208.619 € ., mainly due to decreased NE costs cOnclusiOns: 
Lipegfilgatrim is cost-saving compared with pegfilgrastim. These savings are con-
firmed across a wide range of input values.
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Objectives: There are relatively few treatment options for pre-treated metastatic 
melanoma (MM) patients. Clinicians have recently been provided access to a new 
option, ipilumumab that has demonstrated long-term survival benefits, in a subset 
of patients. Karweit J and colleagues (2012) present data to support the use of mean 
OS for agents with a right-skewed survival curve, where a subset of patients respond 
to treatment with long term survival -as is the case for ipilimumab. The research 
presents data for several oncology agents: ipilimumab for MM, bevacizumab for non-
small cell lung cancer, sorafenib for hepatocellular carcinoma, lenalidomide for mul-
tiple myeloma, trastuzumab for metastatic breast cancer and vemurafenib for MM. 
The data reveals a greater mean OS improvement than median OS improvement, 
since mean OS accurately captures the complete survival benefits. In this analysis 
we select agents from the Krweit J et al study and who have received regulatory 
authorization in Colombia, to compare their relative economic value. MethOds: 
The economic value of each asset is presented in terms of cost per month of mean 
OS within the Colombian health care payer perspective. The analysis uses the cost 
to treat to mean progression of each asset divided by the months of mean overall 
survival improvement using current list prices of assets. Results: Ipilimumab in 
comparison to bevacizumab, sorafenib, trastuzumab, sutinib, lenalidomide, and 
vemurafenib demonstrates a clinical and economic relative value. The cost per mean 
overall survival month gained for ipilumumab ($39,344,362 COP) is below the average 
of the comparator assets (range from $60,226,690 to $20,166,226). cOnclusiOns: 
The relative clinical and economic value of ipilumumab in the context of a variety 
of oncologic assets is clearly documented. This data provides health care decision 
makers critical data when determining coverage of oncologic treatments.
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Objectives: To examine the economic burden and health care utilizations of pros-
tate cancer patients in the U.S. veteran population. MethOds: Patients diagnosed 
with prostate cancer (ICD-9: 185.xx) were identified from the U.S. Veterans Health 
Administration (VHA) Medical SAS dataset from October 1, 2009 through September 
30, 2011. The first diagnosis date was defined as the index date. A comparator group 
was created by identifying patients without prostate cancer but with the same age, 
region, gender, index year, and matched baseline Charlson Comorbidity Index. The 
